Acino has signed an exclusive distribution agreement with the Swedish biopharmaceutical company Sobi in Kazakhstan. The agreement focuses on the distribution of orphan drugs for patients with diseases such as rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, Still's disease, paroxysmal nocturnal hemoglobinuria, tyrosinemia type 1, thrombocytopenia, primary hemophagocytic lymphohistiocytosis and chylomicronemia syndrome.
Acino, a Swiss pharmaceutical company, today announced that it has signed an exclusive distribution agreement with Sobi, a Swedish biopharmaceutical company, to market several orphan drugs: Doptelet®, Aspaveli®, Gamifant®, Kineret®, Orfadin®, Tegsedi®, Waylivra® in Kazakhstan . Under the terms of this five-year agreement, Acino will market and sell Sobi's products in the specialty hospital segment beginning in early 2024.
